Comparison of vascular response to zotarolimus-eluting stent versus sirolimus-eluting stent: Intravascular ultrasound results from ENDEAVOR III.
Miyazawa, Akiyoshi MD a; Ako, Junya MD a; Hongo, Yoichiro MD a; Hur, Seung-Ho MD, PhD a; Tsujino, Ichizo MD, PhD a; Courtney, Brian K. MD a; Hassan, Ali H.M. MD a; Kandzari, David E. MD b; Honda, Yasuhiro MD a; Fitzgerald, Peter J. MD, PhD a; for the ENDEAVOR III Investigators
[Article] American Heart Journal. 155(1):108-113, January 2008.

(Format: HTML, PDF)

Background: The purpose of this study was to investigate the vascular response of zotarolimus-eluting stent (ZES) and sirolimus-eluting stent (SES) using serial intravascular ultrasound (IVUS).

Methods: Data were obtained from the Endeavor Drug-Eluting Coronary Stent System Versus the Center Siromlimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions (ENDEAVOR) III trial, a randomized study comparing ZES and SES for the treatment of de novo native coronary artery lesions. Serial (baseline and 8-month follow-up) IVUS was available in 258 patients (190 ZES, 68 SES).

Results: At 8 months, ZES had greater percentage of neointimal volume index (ZES 1.1 /- 0.8 mm3/mm vs SES 0.2 /- 0.1 mm3/mm, P < .01), resulting in smaller lumen volume index (6.0 /- 2.0 mm3/mm vs 7.0 /- 2.1 mm3/mm, P < .05). Zotarolimus-eluting stents showed larger IVUS-detectable neointimal coverage over stent surface (50.2% vs 10.5%, P < .01) and greater mean neointimal thickness (0.19 /- 0.07 mm vs 0.10 /- 0.06 mm, P < .01). Zotarolimus-eluting stents had a significantly lower incidence of late-acquired incomplete stent apposition.

Conclusions: Zotarolimus-eluting stent is associated with a significantly greater amount of neointimal hyperplasia compared with SES. This amount of hyperplasia in ZES is distributed throughout the stent at 8-month follow-up.

(C) Mosby-Year Book Inc. 2008. All Rights Reserved.